Executive Summary
Bioprosthetic valve failure after TAVR is a real, cumulative, and clinically costly event — 8.3% at 10 years, with independently elevated risks of death (aHR 1.72), cardiovascular death (aHR 3.23), stroke, and HF hospitalization — per a 7,501-patient international registry published in Circulation: Cardiovascular Interventions. Redo-TAVR with self-expanding Evolut valves offers a workable bailout, matching native TAVR mortality and stroke at one year in a TVT Registry analysis of 439 patients in JACC: Cardiovascular Interventions, though residual gradients ran higher (11.3 vs 8.2 mm Hg). Together the two papers reframe the durability conversation: THV failure is not rare, and while a second valve is feasible, hemodynamics don't fully reset — which tightens the case against reflexive TAVI in patients under 70 where ESC 2025 already prefers SAVR.
- BVF predictors include balloon-expandable valves, size <26 mm, ViV procedures, and discharge gradients ≥15 mm Hg — pointing to modifiable index-procedure choices (Circ Cardiovasc Interv).
- In a 683-patient Australian ViV-TAVR registry, supra- and intra-annular self-expanding valves produced comparable gradients, with a non-significant trend toward more MACCE and stroke with intra-annular valves (JACC Cardiovasc Interv).
- In 281 patients with AF and functional MR, upfront AF ablation cut all-cause mortality (3% vs 14%, p=0.002) versus M-TEER-first, despite less MR reduction — a stage-of-disease argument, single-center, retrospective (Heart Rhythm).
- An HCM-trained deep learning model applied to pre-TAVR echoes predicted post-TAVR LVOT obstruction (AUROC 0.84 in patients without baseline LVOTO), flagging a phenotype invisible to conventional Doppler (medRxiv).
- Peijia Medical posted its first profit before tax on TAVR-driven growth, signaling that the Asia-Pacific transcatheter market is now generating operating leverage (PR Newswire).
What to watch: Medtronic's September 1 earnings will be the first read on Evolut demand in a quarter where redo-TAVR data favored the self-expanding platform.
Aortic Valve (TAVR/TAVI)
Durability is a measured, dose-dependent risk. The multicenter international registry in Circulation: Cardiovascular Interventions tracked 7,501 TAVR patients across 13 centers and found BVF in 5.1% over a median 4 years, rising to 8.3% at 10 years, with independent associations to all-cause mortality (aHR 1.72), cardiovascular mortality (aHR 3.23), stroke (aHR 2.08), and HF hospitalization (aHR 1.43). Younger age, smoking, balloon-expandable valves, prosthesis size <26 mm, ViV procedures, and suboptimal discharge hemodynamics all predicted failure — the modifiable list is uncomfortably long. ACC/AHA 2020 reserves TAVI-preferred status for patients >80 on durability grounds; ESC 2025 lowered that threshold to 70, and today's data does not comfort the ESC position for patients on the younger edge of that expansion. [NOTABLE]
The redo pathway works — a TVT Registry analysis in JACC: Cardiovascular Interventions of 439 Evolut redo-TAVR patients showed procedural complications were low and 1-year mortality, stroke, and readmission matched native TAVR after adjustment. But mean gradients stayed higher (11.3 vs 8.2 mm Hg), and as Chakravarty and Makkar note in their accompanying editorial, the second valve is only half the story: coronary access, sinus sequestration, and future explant remain the shadow over lifetime management. A CCI case series on bioprosthetic valve remodeling in failed non-fracturable Trifecta valves adds a further caution — high-pressure balloon remodeling produced pronounced THV deformation and reduced the valve-to-coronary distance from 5 mm to near-zero. ESC 2025 explicitly flags neo-skirt height and coronary obstruction risk as central to lifetime management planning at the index procedure; today's Trifecta data illustrates what happens when that planning is inadequate.
In ViV work, a 683-patient ACOR registry analysis found supra-annular and intra-annular self-expanding valves delivered comparable gradients, but a non-significant trend toward higher MACCE (11.9% vs 7.1%) and stroke (5.4% vs 1.7%) with intra-annular devices deserves prospective confirmation. The HFpEF-ABA score analysis in Heart, Lung and Circulation — 2,175 TAVI patients, retrospective — identified 63.8% with high HFpEF probability who had worse post-TAVI function and more HF hospitalizations despite valve success, reinforcing that a fixed valve doesn't fix the ventricle. Surgical aortic valve replacement eliminates prosthesis-within-prosthesis hemodynamic penalties entirely in the index procedure; that advantage compounds when lifetime management requires a third intervention.
Mitral Valve (MitraClip, PASCAL, TMVR)
The sequencing question in AF plus functional MR just got harder for the TEER-first camp. A single-center retrospective analysis in Heart Rhythm of 281 patients with AF and moderate to moderate-severe FMR compared upfront AF ablation (n=152) versus M-TEER (n=129). TEER reduced MR severity more effectively (p<0.001), as expected. Ablation-first delivered better symptom stability (69% vs 44%), markedly lower two-year all-cause mortality (3% vs 14%, p=0.002), fewer cardiac hospitalizations, and better LVEF recovery (53% vs 47%). The authors frame this as stage-dependent management rather than treatment superiority: patients selected for ablation-first likely had earlier, atrial-driven disease amenable to rhythm control, while TEER-first patients were further downstream. Retrospective, single-center, non-randomized — the mortality signal is large enough, however, that the field cannot keep clipping every AF-driven MR without asking about the rhythm first.
The finding aligns with ESC 2025's formal recognition of atrial secondary MR as a distinct entity where rhythm restoration and left atrial reverse remodeling are foundational. ESC 2025 rates TEER Class IIb for atrial SMR only when patients are inoperable; ACC/AHA 2020 offers no formal atrial SMR pathway. Separately, a Circulation editorial by Rose and Spadaccio argues that current procedural success definitions in transcatheter mitral repair set the bar too low — a point the surgical community has made about ≤2+ residual MR endpoints since COAPT.
Tricuspid Valve (TriClip, TTVR)
No new tricuspid trial data today. The Heart Rhythm AF/MR paper is worth flagging here: TR was not the endpoint but travels with atrial SMR, and the mortality difference favoring rhythm-first management may extend to tricuspid disease driven by atrial dilation — an inference the ESC 2025 framework explicitly considers. ESC 2025 rates transcatheter TV treatment Class IIa (LOE A) for high-risk symptomatic severe TR; ACC/AHA 2020 offers no recommendation because the trials post-dated its writing. The gap will not close until the next ACC/AHA update integrates TRILUMINATE Pivotal, Tri.Fr, and TRISCEND II.
Surgical vs. Transcatheter Comparisons
No head-to-head SAVR vs TAVR data today. The 8.3% BVF at 10 years is not directly comparable to surgical bioprosthetic SVD rates — BVF is a broader endpoint — but younger age independently predicting failure is exactly the population ESC 2025 shifted toward TAVI at age 70. ACC/AHA 2020 retains SAVR preference below 65 and shared decision-making from 65–80 precisely because long-term durability data were incomplete; today's paper does not rebut that caution. A JACC: Cardiovascular Interventions editorial on conduction disturbances after TAVR emphasizes that residual cardiac damage stratifies outcomes — a reminder that the ventricle and conduction system surviving TAVR is not always equivalent to what would have survived SAVR.
Preprint Highlights
A medRxiv preprint from a 302-patient retrospective cohort applied a deep learning model originally trained on hypertrophic cardiomyopathy echoes to predict post-TAVR LVOT gradient elevation. The DLi-LVOTO index — derived from resting parasternal long-axis 2D video without Doppler — independently predicted post-TAVR Doppler-defined LVOTO (adjusted OR 1.24 per 10-point increase; AUROC 0.78 overall, 0.84 in patients without baseline LVOTO). Post-TAVR LVOTO occurred in 11.6%. If this reproduces prospectively, it would identify a phenotype pre-procedure that conventional imaging misses — relevant for valve sizing, positioning, and post-procedure surveillance. Not yet peer-reviewed.
Industry & Market
Peijia Medical reported first-ever profit before tax at 2026 interim results, driven by TAVR growth in the Chinese and adjacent Asia-Pacific markets. As Western trials wrestle with durability and lifetime management, emerging-market TAVR volumes are climbing on populations that skew older and have shorter expected valve lifespans — a different risk-benefit calculus than ESC 2025's age-70 threshold assumes.
Financial Analysis
Edwards continues to grind higher on institutional accumulation — multiple new institutional positions this week against a clinical backdrop where balloon-expandable valves were flagged as a BVF predictor in today's Circulation paper. The durability question is now specific enough that platform choice matters for lifetime planning — an underappreciated headwind for Edwards that the market has not yet priced. Boston Scientific's continued slide — down 33% over six months — reflects post-guidance repricing more than valve-specific news, but the stock's weakness is a structural repricing. Medtronic reports September 1; today's Evolut redo-TAVR data offers the platform a genuine talking point on lifetime management.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Close $90.50, +0.79% on the day, +8.51% over six months
- Market cap $52.1B, trailing P/E 53.55, forward P/E 26.79, beta 0.85
- 52-week range $72.30–$96.29
- Analyst consensus target $100.96 (range $84–$110, 26 analysts), Buy
- Next earnings October 29 (EPS est $0.74, revenue est $1.68B)
Multiple institutional buys this week; today's BVF data implicating balloon-expandable valves is a clinical wrinkle worth watching but has not yet moved the stock.
Medtronic (MDT)
- Close $92.90, -0.48% on the day, -2.22% over six months
- Market cap $118.9B, trailing P/E 24.97, forward P/E 14.49, beta 0.57
- 52-week range $73.31–$106.33
- Analyst consensus target $98.44 (range $78–$121, 25 analysts), Buy
- Next earnings September 1 (EPS est $1.39, revenue est $9.54B)
Today's Evolut redo-TAVR paper lands directly ahead of earnings — a favorable lifetime-management narrative for structural heart franchise commentary.
Abbott (ABT)
- Close $116.67, +0.03% on the day, +3.03% over six months
- Market cap $203.2B, trailing P/E 37.76, forward P/E 19.24, beta 0.58
- 52-week range $81.97–$137.49
- Analyst consensus target $120.20 (range $103–$135, 25 analysts), Buy
- Next earnings October 14 (EPS est $1.42, revenue est $12.99B)
TriClip continues to benefit from ESC 2025's Class IIa endorsement for transcatheter TV treatment; the AF-first MR data today is a neutral read for MitraClip.
Boston Scientific (BSX)
- Close $49.01, -2.70% on the day, -33.30% over six months
- Market cap $71.0B, trailing P/E 20.42, forward P/E 14.27, beta 0.57
- 52-week range $42.20–$109.50
- Analyst consensus target $62.69 (range $44–$94, 29 analysts), Buy
- Next earnings October 28 (EPS est $0.81, revenue est $5.26B)
Guidance-driven repricing continues; ACURATE neo2 exit still weighs on structural heart narrative.
Anteris Technologies (AVR.AX)
- Close A$12.07, -2.11% on the day, +40.35% over six months
- Market cap A$1.2B, forward P/E -5.57
- 52-week range A$5.20–$15.47
- Analyst target A$13.00 (1 analyst), Hold
Continues to run on DurAVR speculation; no company-specific catalyst today.
Market outlook: Today's BVF paper is a slow-burn negative for TAVR platforms generally and balloon-expandable valves specifically, but the redo-TAVR bailout data softens the blow. The market has not yet priced durability differentiation across THV platforms — an inefficiency likely to correct as 10-year data accumulates. Peijia's profitability turn is the more interesting near-term signal on Asia-Pacific market maturation.
Clinical Trial Updates
No new trial launches or interim readouts today. The Evolut redo-TAVR TVT Registry analysis is the most consequential real-world dataset to publish this week.
Social & Conference Highlights
TCTMD ran a TAVR Masterclass on aortic ViV procedures with high coronary occlusion risk — timely given today's Trifecta remodeling case series showing valve-to-coronary distance can collapse from 5 mm to near-zero after aggressive balloon inflation. BASILICA and chimney-stenting techniques remain the field's answers, but neither is casual.
The next data point that matters: Medtronic's September 1 earnings call, where redo-TAVR commentary on the Evolut platform will be scrutinized against a durability landscape that just got quantitatively harder to ignore.